-
1
-
-
35848930961
-
Hodgkin's disease- From pathology specimen to cure
-
Diehl V. Hodgkin's disease- From pathology specimen to cure. N Engl J Med 2007; 357:1968-1971.
-
(2007)
N Engl J Med
, vol.357
, pp. 1968-1971
-
-
Diehl, V.1
-
2
-
-
23044452477
-
Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group
-
Meyer RM, Gospodarowicz MK, Connors JM, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 2005; 23:4634-4642.
-
(2005)
J Clin Oncol
, vol.23
, pp. 4634-4642
-
-
Meyer, R.M.1
Gospodarowicz, M.K.2
Connors, J.M.3
-
3
-
-
24944460608
-
First results of the EORTC-GELA H9 randomized trials: The H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin's lymphoma (HL)
-
561s; abstract 6505
-
Noordijk EM, Thomas J, Ferme C, et al. First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin's lymphoma (HL). J Clin Oncol 2005; 23:561s; abstract 6505.
-
(2005)
J Clin Oncol
, vol.23
-
-
Noordijk, E.M.1
Thomas, J.2
Ferme, C.3
-
4
-
-
46749138836
-
Doxorubicin, Vinblastine and Gemci-tabine (AVG), a novel regimen excluding Bleomycin for the treatment of early stage Hodgkin lymphoma (HL): Results of CALGB 50203
-
abstract 214
-
Straus D, LaCase A, Juweid M, et al. Doxorubicin, Vinblastine and Gemci-tabine (AVG), a novel regimen excluding Bleomycin for the treatment of early stage Hodgkin lymphoma (HL): results of CALGB 50203. Blood 2007; 110:70a; abstract 214.
-
(2007)
Blood
, vol.110
-
-
Straus, D.1
LaCase, A.2
Juweid, M.3
-
5
-
-
33646811123
-
HD10: Investigating reduction of combined modality treatment intensity in early stage Hodgkin's lymphoma. Interim analysis of a randomized trial of the German Hodgkin Study Group (GHSG)
-
561s; abstract 6506
-
Diehl V, Brillant C, Engert A, et al. HD10: investigating reduction of combined modality treatment intensity in early stage Hodgkin's lymphoma. Interim analysis of a randomized trial of the German Hodgkin Study Group (GHSG). J Clin Oncol 2005; 23:561s; abstract 6506.
-
(2005)
J Clin Oncol
, vol.23
-
-
Diehl, V.1
Brillant, C.2
Engert, A.3
-
6
-
-
35848959692
-
Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease
-
Ferme C, Eghbali H, Meerwaldt JH, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med 2007; 357:191 6-1927.
-
(2007)
N Engl J Med
, vol.357
, Issue.191
, pp. 6-1927
-
-
Ferme, C.1
Eghbali, H.2
Meerwaldt, J.H.3
-
7
-
-
31144465569
-
ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: Final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi
-
Gobbi PG, Levis A, Chisesi T, et al. ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol 2005; 23:9198-9207.
-
(2005)
J Clin Oncol
, vol.23
, pp. 9198-9207
-
-
Gobbi, P.G.1
Levis, A.2
Chisesi, T.3
-
8
-
-
33644818361
-
Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: Results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519)
-
Johnson PWM, Radford JA, Cullen MH, et al. Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). J Clin Oncol 2005; 23:9208-9218.
-
(2005)
J Clin Oncol
, vol.23
, pp. 9208-9218
-
-
Johnson, P.W.M.1
Radford, J.A.2
Cullen, M.H.3
-
10
-
-
34249285155
-
G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: Low toxicity and excellent outcomes in a 10-year analysis
-
Evens AM, Cilley J, Ortiz T, et al. G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. Br J Haematol 2007; 137:545-552.
-
(2007)
Br J Haematol
, vol.137
, pp. 545-552
-
-
Evens, A.M.1
Cilley, J.2
Ortiz, T.3
-
11
-
-
33847270617
-
ABVD for Hodgkin's lymphoma: Full-dose chemotherapy without dose reductions or growth factors
-
Boleti E, Mead GM. ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors. Ann Oncol 2007; 18:376-380.
-
(2007)
Ann Oncol
, vol.18
, pp. 376-380
-
-
Boleti, E.1
Mead, G.M.2
-
12
-
-
32944468191
-
Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma
-
Martin WG, Ristow KM, Habermann TM, et al. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. J Clin Oncol 2005; 23:7614-7620.
-
(2005)
J Clin Oncol
, vol.23
, pp. 7614-7620
-
-
Martin, W.G.1
Ristow, K.M.2
Habermann, T.M.3
-
13
-
-
0036467658
-
Stanford Vand radiotherapy for locally extensive and advanced Hodgkin's disease: Mature results of a prospective clinical trial
-
Horning SJ, Hoppe RT, Breslin S, et al. Stanford Vand radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol 2002; 20:630-637.
-
(2002)
J Clin Oncol
, vol.20
, pp. 630-637
-
-
Horning, S.J.1
Hoppe, R.T.2
Breslin, S.3
-
14
-
-
0037567428
-
Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease
-
Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003; 348:2386-2395.
-
(2003)
N Engl J Med
, vol.348
, pp. 2386-2395
-
-
Diehl, V.1
Franklin, J.2
Pfreundschuh, M.3
-
15
-
-
59449100046
-
Long-term follow-up of BEACOPP escalated chemotherapy in patients with advanced-stage Hodgkin lymphoma on behalf of the German Hodgkin Study Group
-
abstract 211
-
Andreas E, Franklin J, Diehl V. Long-term follow-up of BEACOPP escalated chemotherapy in patients with advanced-stage Hodgkin lymphoma on behalf of the German Hodgkin Study Group. Blood 2007; 110:70a; abstract 211.
-
(2007)
Blood
, vol.110
-
-
Andreas, E.1
Franklin, J.2
Diehl, V.3
-
16
-
-
0032548107
-
A prognostic score for advanced Hodgkin's disease
-
Hasenclever D, Diehl V, Armitage JO, et al. A prognostic score for advanced Hodgkin's disease. N Engl J Med 1998; 339:1506-1514.
-
(1998)
N Engl J Med
, vol.339
, pp. 1506-1514
-
-
Hasenclever, D.1
Diehl, V.2
Armitage, J.O.3
-
17
-
-
68449090699
-
Rituximab + ABVD improves event-free survival (EFS) in patients with classical Hodgkin lymphoma in all International Prognostic Score (IPS) Groups and in patients who have PET positive disease after 2 3 cycles of therapy
-
abstract 215
-
Wedgwood AR, Fanale MA, Fayad LE, et al. Rituximab + ABVD improves event-free survival (EFS) in patients with classical Hodgkin lymphoma in all International Prognostic Score (IPS) Groups and in patients who have PET positive disease after 2 3 cycles of therapy. Blood 2007; 110:71a; abstract 215.
-
(2007)
Blood
, vol.110
-
-
Wedgwood, A.R.1
Fanale, M.A.2
Fayad, L.E.3
-
18
-
-
37349064204
-
Clonotypic B cells circulate in Hodgkin's lymphoma (HL)
-
abstract 470
-
Jones RJ, Lin L, Gocke C, et al. Clonotypic B cells circulate in Hodgkin's lymphoma (HL). Blood 2006; 108:143a; abstract 470.
-
(2006)
Blood
, vol.108
-
-
Jones, R.J.1
Lin, L.2
Gocke, C.3
-
19
-
-
30144432586
-
FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma
-
Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006; 107:52-59.
-
(2006)
Blood
, vol.107
, pp. 52-59
-
-
Hutchings, M.1
Loft, A.2
Hansen, M.3
-
20
-
-
33645998113
-
The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease
-
Gallamini A, Rigacci L, Merli F, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica 2006; 91:475-481.
-
(2006)
Haematologica
, vol.91
, pp. 475-481
-
-
Gallamini, A.1
Rigacci, L.2
Merli, F.3
-
21
-
-
34548486030
-
Early Interim 2-[18F]Fluoro-2- Deoxy-D-Glucose positron emission tomography is prognostically superior to International Prognostic Score in advanced-stage Hodgkin's lymphoma: A report from a joint Italian-Danish Study
-
Gallamini A, Hutchings M, Rigacci L, et al. Early Interim 2-[18F]Fluoro-2- Deoxy-D-Glucose positron emission tomography is prognostically superior to International Prognostic Score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish Study. J Clin Oncol 2007; 25:3746-3752.
-
(2007)
J Clin Oncol
, vol.25
, pp. 3746-3752
-
-
Gallamini, A.1
Hutchings, M.2
Rigacci, L.3
-
22
-
-
34548541713
-
Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease
-
Advani R, Maeda L, Lavori P, et al. Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease. J Clin Oncol 2007; 25:3902-3907.
-
(2007)
J Clin Oncol
, vol.25
, pp. 3902-3907
-
-
Advani, R.1
Maeda, L.2
Lavori, P.3
-
23
-
-
33846863991
-
Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome
-
Dann EJ, Bar-Shalom R, Tamir A, et al. Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. Blood 2007; 109: 905-909.
-
(2007)
Blood
, vol.109
, pp. 905-909
-
-
Dann, E.J.1
Bar-Shalom, R.2
Tamir, A.3
-
24
-
-
0027404777
-
Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial
-
Linch DC, Goldstone AH, McMillan A, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. The Lancet 1993; 341:1051-1054.
-
(1993)
The Lancet
, vol.341
, pp. 1051-1054
-
-
Linch, D.C.1
Goldstone, A.H.2
McMillan, A.3
-
25
-
-
66649134821
-
-
Long term follow up in relapsed Hodgkin's disease (HD): Updated results of the HD-R1 study comparing conventional chemotherapy (cCT) to high-dose chemotherapy (HDCT) with autologous haemopoietic stem cell transplantation (ASCT) of the German Hodgkin Study Group (GHSG) and the Working Party Lymphoma of the European Group for Blood and Marrow Transplantation (EBMT), 567s; abstract 6508
-
Schmitz N, Haverkamp H, Josting A, et al. Long term follow up in relapsed Hodgkin's disease (HD): updated results of the HD-R1 study comparing conventional chemotherapy (cCT) to high-dose chemotherapy (HDCT) with autologous haemopoietic stem cell transplantation (ASCT) of the German Hodgkin Study Group (GHSG) and the Working Party Lymphoma of the European Group for Blood and Marrow Transplantation (EBMT). J Clin Oncol 2005; 23:567s; abstract 6508.
-
(2005)
J Clin Oncol
, vol.23
-
-
Schmitz, N.1
Haverkamp, H.2
Josting, A.3
-
26
-
-
20944446433
-
Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse
-
Sureda A, Constans M, Iriondo A, et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol 2005; 16:625-633.
-
(2005)
Ann Oncol
, vol.16
, pp. 625-633
-
-
Sureda, A.1
Constans, M.2
Iriondo, A.3
-
27
-
-
1542359509
-
Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease
-
Moskowitz CH, Kewalramani T, Nimer SD, et al. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. Br J Haematol 2004; 124:645-652.
-
(2004)
Br J Haematol
, vol.124
, pp. 645-652
-
-
Moskowitz, C.H.1
Kewalramani, T.2
Nimer, S.D.3
-
28
-
-
34249949761
-
Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma
-
Sieniawski M, Franklin J, Nogova L, et al. Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma. J Clin Oncol 2007; 25:2000-2005.
-
(2007)
J Clin Oncol
, vol.25
, pp. 2000-2005
-
-
Sieniawski, M.1
Franklin, J.2
Nogova, L.3
-
29
-
-
34447320514
-
Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804
-
Bartlett NL, Niedzwiecki D, Johnson JL, et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol 2007; 18:1071-1079.
-
(2007)
Ann Oncol
, vol.18
, pp. 1071-1079
-
-
Bartlett, N.L.1
Niedzwiecki, D.2
Johnson, J.L.3
-
30
-
-
30744445985
-
-
Kuruvilla J, Nagy T, Pintilie M, et al. Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and mel-phalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma. Cancer 2006; 106:353-360.
-
Kuruvilla J, Nagy T, Pintilie M, et al. Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and mel-phalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma. Cancer 2006; 106:353-360.
-
-
-
-
31
-
-
34250223441
-
Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/ refractory Hodgkin lymphoma
-
Jabbour E, Hosing C, Ayers G, et al. Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/ refractory Hodgkin lymphoma. Cancer 2007; 109:2481-2489.
-
(2007)
Cancer
, vol.109
, pp. 2481-2489
-
-
Jabbour, E.1
Hosing, C.2
Ayers, G.3
-
32
-
-
33846213431
-
Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma
-
Schot BW, Zijlstra JM, Sluiter WJ, et al. Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Blood 2007; 109:486-491.
-
(2007)
Blood
, vol.109
, pp. 486-491
-
-
Schot, B.W.1
Zijlstra, J.M.2
Sluiter, W.J.3
-
33
-
-
0038702514
-
An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: Allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation
-
Peniket AJ, Ruiz de Elvira MC, Taghipour G, et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 2003; 31:667-678.
-
(2003)
Bone Marrow Transplant
, vol.31
, pp. 667-678
-
-
Peniket, A.J.1
Ruiz de Elvira, M.C.2
Taghipour, G.3
-
34
-
-
9444272217
-
Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: A report of the International Bone Marrow Transplant Registry
-
Freytes CO, Loberiza FR, Rizzo JD, et al. Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry. Blood 2004; 104:3797-3803.
-
(2004)
Blood
, vol.104
, pp. 3797-3803
-
-
Freytes, C.O.1
Loberiza, F.R.2
Rizzo, J.D.3
-
35
-
-
20444410110
-
Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation
-
Peggs KS, Hunter A, Chopra R, et al. Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. The Lancet 2005; 365:1934-1941.
-
(2005)
The Lancet
, vol.365
, pp. 1934-1941
-
-
Peggs, K.S.1
Hunter, A.2
Chopra, R.3
-
36
-
-
38649089434
-
Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: An analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
-
Sureda A, Robinson S, Canals C, et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008; 26:455-462.
-
(2008)
J Clin Oncol
, vol.26
, pp. 455-462
-
-
Sureda, A.1
Robinson, S.2
Canals, C.3
-
38
-
-
34447573999
-
Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma
-
Ansell SM, Horwitz SM, Engert A, et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 2007; 25:2764-2769.
-
(2007)
J Clin Oncol
, vol.25
, pp. 2764-2769
-
-
Ansell, S.M.1
Horwitz, S.M.2
Engert, A.3
-
39
-
-
0042738861
-
cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity
-
Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003; 102:1458-1465.
-
(2003)
Blood
, vol.102
, pp. 1458-1465
-
-
Francisco, J.A.1
Cerveny, C.G.2
Meyer, D.L.3
-
40
-
-
53049084469
-
A novel antibody-drug conjugate, SNG-35 (Anti-CD30-Auristatin), induces objective responses in patients with relapsed or refractory Hodgkin lymphoma: Preliminary results of a phase I tolerability study
-
abstract PO99bis
-
Younes A, Forero-Torres A, Bartlett NL, et al. A novel antibody-drug conjugate, SNG-35 (Anti-CD30-Auristatin), induces objective responses in patients with relapsed or refractory Hodgkin lymphoma: preliminary results of a phase I tolerability study. Haematologica 2007; 92:64; abstract PO99bis.
-
(2007)
Haematologica
, vol.92
, pp. 64
-
-
Younes, A.1
Forero-Torres, A.2
Bartlett, N.L.3
-
41
-
-
34447566086
-
Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: Cancer and Leukemia Group B protocol 50206
-
Blum KA, Johnson JL, Niedzwiecki D, et al. Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: Cancer and Leukemia Group B protocol 50206. Leuk Lymphoma 2007; 48:1313-1319.
-
(2007)
Leuk Lymphoma
, vol.48
, pp. 1313-1319
-
-
Blum, K.A.1
Johnson, J.L.2
Niedzwiecki, D.3
-
42
-
-
34548542892
-
A phase II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor in patients with relapsed or refractory Hodgkin lymphoma
-
441s; abstract 8000
-
Younes A, Fanale M, Pro B, et al. A phase II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor in patients with relapsed or refractory Hodgkin lymphoma. J Clin Oncol 2007; 25:441s; abstract 8000.
-
(2007)
J Clin Oncol
, vol.25
-
-
Younes, A.1
Fanale, M.2
Pro, B.3
-
43
-
-
33644836549
-
Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies
-
O'Connor OA, Heaney ML, Schwartz L, et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 2006; 24:166-173.
-
(2006)
J Clin Oncol
, vol.24
, pp. 166-173
-
-
O'Connor, O.A.1
Heaney, M.L.2
Schwartz, L.3
-
44
-
-
33644832050
-
A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin's lymphoma
-
Kuruvilla J, Song K, Mollee P, et al. A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin's lymphoma. Hematology 2006; 11:25-29.
-
(2006)
Hematology
, vol.11
, pp. 25-29
-
-
Kuruvilla, J.1
Song, K.2
Mollee, P.3
-
45
-
-
0033013787
-
Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: Report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease
-
Diehl V, Sextro M, Franklin J, et al. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. J Clin Oncol 1999; 17:776-783.
-
(1999)
J Clin Oncol
, vol.17
, pp. 776-783
-
-
Diehl, V.1
Sextro, M.2
Franklin, J.3
-
46
-
-
38649125204
-
Lymphocyte-predominant and classical Hodgkin's lymphoma: A comprehensive analysis from the German Hodgkin Study Group
-
Nogova L, ReinekeT, Brillant C, et al. Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol 2008; 26:434-439.
-
(2008)
J Clin Oncol
, vol.26
, pp. 434-439
-
-
Nogova, L.1
Reineke, T.2
Brillant, C.3
-
47
-
-
34250793304
-
Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma
-
Mauz-Korholz C, Gorde-Grosjean S, Hasenclever D, et al. Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma. Cancer 2007; 110:179-185.
-
(2007)
Cancer
, vol.110
, pp. 179-185
-
-
Mauz-Korholz, C.1
Gorde-Grosjean, S.2
Hasenclever, D.3
-
48
-
-
38049162295
-
Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: Long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)
-
Schulz H, Rehwald U, Morschhauser F, et al. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood 2008; 111:109 - 111.
-
(2008)
Blood
, vol.111
, pp. 109-111
-
-
Schulz, H.1
Rehwald, U.2
Morschhauser, F.3
-
49
-
-
34250698040
-
Nodular lymphocyte-predominant Hodgkin lymphoma
-
Tsai HK, Mauch PM. Nodular lymphocyte-predominant Hodgkin lymphoma. Semin Radiat Oncol 2007; 17:184-189.
-
(2007)
Semin Radiat Oncol
, vol.17
, pp. 184-189
-
-
Tsai, H.K.1
Mauch, P.M.2
-
50
-
-
27144479926
-
Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: A retrospective analysis from the German Hodgkin Study Group (GHSG)
-
Nogova L, Reineke T, Eich HT, et al. Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG). Ann Oncol 2005; 16:1683-1687.
-
(2005)
Ann Oncol
, vol.16
, pp. 1683-1687
-
-
Nogova, L.1
Reineke, T.2
Eich, H.T.3
-
51
-
-
51649083254
-
Results of a prospective phase II trial of limited and extended rituximab treatment in nodular lymphocyte predominant Hodgkin's disease (NLPHD)
-
abstract 644
-
Horning SJ, Bartlett NL, Breslin S, et al. Results of a prospective phase II trial of limited and extended rituximab treatment in nodular lymphocyte predominant Hodgkin's disease (NLPHD). Blood 2007; 110:198a; abstract 644.
-
(2007)
Blood
, vol.110
-
-
Horning, S.J.1
Bartlett, N.L.2
Breslin, S.3
-
52
-
-
0030747027
-
Clinical presentation and outcome in lymphocyte-predominant Hodgkin's disease
-
Bodis S, Kraus MD, Pinkus G, et al. Clinical presentation and outcome in lymphocyte-predominant Hodgkin's disease. J Clin Oncol 1997; 15:3060-3066.
-
(1997)
J Clin Oncol
, vol.15
, pp. 3060-3066
-
-
Bodis, S.1
Kraus, M.D.2
Pinkus, G.3
-
53
-
-
34250703560
-
Screening for coronary artery disease after mediastinal irradiation for Hodgkin's disease
-
Heidenreich PA, Schnittger I, Strauss HW, et al. Screening for coronary artery disease after mediastinal irradiation for Hodgkin's disease. J Clin Oncol 2007; 25:43-49.
-
(2007)
J Clin Oncol
, vol.25
, pp. 43-49
-
-
Heidenreich, P.A.1
Schnittger, I.2
Strauss, H.W.3
-
54
-
-
27244437759
-
Stroke as a late treatment effect of Hodgkin's disease: A report from the Childhood Cancer Survivor Study
-
Bowers DC, McNeil DE, Liu Y, et al. Stroke as a late treatment effect of Hodgkin's disease: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2005; 23:6508-6515.
-
(2005)
J Clin Oncol
, vol.23
, pp. 6508-6515
-
-
Bowers, D.C.1
McNeil, D.E.2
Liu, Y.3
-
56
-
-
34047137002
-
American Cancer Society Guidelines for breast screening with MRI as an adjunct to mammography
-
Saslow D, Boetes C, Burke W, et al. American Cancer Society Guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007; 57:75-89.
-
(2007)
CA Cancer J Clin
, vol.57
, pp. 75-89
-
-
Saslow, D.1
Boetes, C.2
Burke, W.3
|